NCM · Biotechnology

Revelation Biosciences, Inc. (REVB) Stock

$0.76 -1.81% NCM: REVB Healthcare

Valuation

MetricValue
Price$0.76
Market Cap$2.97M
P/E Ratio-0.11
P/B Ratio0.29
P/S Ratio0.00
EPS (TTM)$-23.95
52-Week High$6.76
52-Week Low$0.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.20%
ROA-86.02%
ROCE-106.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.07
Current Ratio5.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-11.0M$-9.0M$-8.0M$-9.0M
Net Profit$-12.0M$-11.0M$0$-15.0M$-9.0M
EPS$-20400.00$-9643.37$-8.41$-87.68$-23.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0M$6.0M$12.0M$7.0M$12.0M
Total Liabilities$2.0M$4.0M$6.0M$2.0M$3.0M
Cash$1.0M$5.0M$12.0M$6.0M$11.0M
Borrowings$0$0$0$0$1.0M

Latest News

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESS Newswire · Jul 21, 2026 Revelation Biosciences Adopts Stockholder Rights Plan MT Newswires · Jul 10, 2026 Revelation Biosciences Announces Adoption of Stockholder Rights Plan ACCESS Newswire · Jul 10, 2026 Revelation Biosciences Expands Acute Kidney Injury Advisory Board ACCESS Newswire · Jun 1, 2026 Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders ACCESS Newswire · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-11.0M$-7.0M$-18.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$12.0M$0$0$0
Net Cash Flow$-3.0M$4.0M$7.0M$-5.0M$4.0M
Free Cash Flow$-11.0M$-11.0M$-7.0M$-18.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.71
FCF Yield-316.29%
Quick Ratio6.21
Interest Coverage0.00
Return 1Y-90.51%
Return 3Y-99.98%
Return 5Y-100.00%

Ownership

Insiders Held4.79%
Institutions Held12.79%
Institutions Float Held13.43%
Institutional HolderSharesReport Date
Armistice Capital, LLC323,2412026-03-31
Sabby Management, LLC99,4322026-03-31
Geode Capital Management, LLC43,1952026-03-31
Vanguard Fiduciary Trust Co13,1272026-03-31
Xtx Topco Ltd11,3852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
AZTRAzitra Inc $0.13 -1.59% -0.10 $1.40M 0.00%
GTBPGT Biopharma, Inc. $6.68 +12.08% -0.06 $8.43M 0.00%
INDPIndaptus Therapeutics, Inc. $2.51 +5.91% -0.34 $284.24M 0.00%
NKGNNKGen Biotech, Inc. $0.06 +0.00% -0.04 $7.84M 0.00%

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is led by CEO James Rolke, employs 8 people, headquartered in US, publicly traded since 2020.

Revelation Biosciences, Inc. (REVB) stock trades at $0.76 with a market capitalization of $2.97M. The stock is valued at a price-to-earnings (P/E) ratio of -0.11, price-to-book of 0.29, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.75 and $6.76, and currently trades 88.8% below its 52-week high.

On profitability, Revelation Biosciences, Inc. generates a return on equity (ROE) of -100.20%, return on capital employed of -106.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides